Acknowledgement
This editorial is dedicated to RJ Griffin (1955–2014), a brilliant academic medicinal chemist and key member of the Newcastle team that contributed to the development of the anticancer drug Rucaparib.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.